Related Experiment Video
Updated: May 5, 2026
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Assaying for BRAF V600E in tissue and blood in melanoma
David J Panka1, James W Mier, Ryan J Sullivan
1Beth Israel Deaconess Medical Center, Boston, MA, USA.
Abstract:
The Braf(V600E) mutation has been detected in patients with metastatic melanoma, colon, thyroid, and other cancers. Studies suggested that tumors with this mutation are especially sensitive to BRAF inhibitors-hence the need to reliably determine the BRAF status of tumor specimens. The present technologies used to screen for this mutation fail to address the problems associated with infiltrating stromal and immune cells bearing wild-type BRAF alleles and thus may fail to detect the presence of mutant BRAF(V600E) tumors. We have developed a rapid, inexpensive method of BRAF analysis that reduces the contamination of wild-type BRAF sequences from tumor biopsies. The protocol involves a series of PCR amplifications and restriction digestions that take advantage of unique features of both wild-type and mutant BRAF RNA at codon 600. Using this protocol, mutant BRAF can be detected in RNA from mixed populations with as few as 0.1 % BRAF(V600E) mutant containing cells.
Insights
Accurately detect BRAF V600E mutations in cancer biopsies. This new method reliably identifies mutant BRAF in mixed cell populations, crucial for targeted cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The BRAF V600E mutation is prevalent in various cancers, including melanoma, colon, and thyroid.
- Tumors with BRAF V600E mutations show sensitivity to BRAF inhibitors, necessitating accurate diagnostic methods.
- Current screening technologies struggle with wild-type BRAF allele contamination from stromal and immune cells, potentially leading to false negatives.
Purpose of the Study:
- To develop a reliable and sensitive method for detecting the BRAF V600E mutation in tumor specimens.
- To overcome limitations of existing technologies in distinguishing mutant BRAF from wild-type alleles in mixed cell populations.
Main Methods:
- A novel protocol involving sequential Polymerase Chain Reaction (PCR) amplifications and restriction digestions.
- Exploitation of unique RNA sequence features at codon 600 for differentiating wild-type and mutant BRAF alleles.
- Application to mixed cell populations to assess detection sensitivity.
Main Results:
- The developed method effectively reduces contamination from wild-type BRAF sequences in tumor biopsies.
- Accurate detection of BRAF V600E mutations is achievable even in samples with as low as 0.1% mutant cells.
- The protocol is rapid and cost-effective.
Conclusions:
- This innovative BRAF analysis method offers improved accuracy and sensitivity for detecting the V600E mutation.
- The technique is valuable for precise tumor profiling and guiding BRAF inhibitor-based cancer therapies.
- It addresses a critical need for reliable BRAF status determination in clinical oncology.
